Franklyn Prendergast Net Worth

Franklyn Prendergast biography

Dr. Franklyn G. Prendergast M.D., Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. serves as Independent Director of the Company. Dr. Prendergast retired from the Mayo Clinic in 2014 and is currently the Emeritus Edmond and Marion Guggenheim Professor of Biochemistry and Molecular Biology and Emeritus Professor of Molecular Pharmacology and Experimental Therapeutics at Mayo Medical School. At the Mayo Clinic, he served in several capacities, most significantly, as the Director for Research 1989 – 1992, inclusive, Member of the Mayo Clinic Board of Governors and Executive Committee 1991 – 2007, and Member of the Mayo Clinic Board of Trustees from 1991-2009, inclusive. From 1994 to 2006, he served as a director of Mayo Clinic Cancer Center. He also previously held several other teaching positions at the Mayo Medical School from 1975 through 2014. Dr. Prendergast has served for the National Institute of Health on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; and the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the National Institute of Health and the National Research Council of the National Academy of Sciences. He is also a member of the board of directors of Medibio Limited (ASX:MEB) (OTCQB:MDBIF) and the Infectious Disease Research Institute (IDRI), and he previously served on the board of directors of Eli Lilly & Co. from 1995 to 2017 and was a member of the board’s science and technology committee and public policy and compliance committee. Dr. Prendergast obtained his medical degree with honors from the University of West Indies and attended Oxford University as a Rhodes Scholar, earning an M.A. degree in physiology. He obtain

What is the salary of Franklyn Prendergast?

As the Independent Director of NeuBase Therapeutics, the total compensation of Franklyn Prendergast at NeuBase Therapeutics is $847,371. There are 2 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.

How old is Franklyn Prendergast?

Franklyn Prendergast is 75, he's been the Independent Director of NeuBase Therapeutics since 2019. There are no older and 10 younger executives at NeuBase Therapeutics.

What's Franklyn Prendergast's mailing address?

Franklyn's mailing address filed with the SEC is C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON, PA, 19341.

Insiders trading at NeuBase Therapeutics

Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan et Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.

What does NeuBase Therapeutics do?

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NeuBase Therapeutics executives and stock owners

NeuBase Therapeutics executives and other stock owners filed with the SEC include:

• Dietrich Stephan,
  President, Chief Executive Officer, Director
• Sam Backenroth,
  Chief Financial Officer, Treasurer, Secretary
• Eric Richman,
  Independent Director
• Franklyn Prendergast,
  Independent Director
• Diego Miralles,
  Independent Director
• Dov Goldstein,
  Independent Director
• Dr. Dietrich A. Stephan Ph.D.,
  Founder, Pres, CEO, Chairman & Interim CFO
• Dr. William Roland Mann MBA, Ph.D.,
  Chief Operating Officer
• Samuel Backenroth,
  CFO, Treasurer & Sec.
• Dan Ferry,
  IR Contact Officer
• William Mann,
  Chief Operating Officer
• Dr. Sandra Rojas-Caro M.D.,
  Chief Medical Officer
• Shannon McCarthy,
  Chief People Officer
• Alan Scrivner J.D.,
  VP of IP & Legal
• Dr. Anthony Rossomando Ph.D.,
  Chief Technology Officer
• Dr. Robert Zamboni Ph.D.,
  Chief of Preclinical Devel. & Member of Scientific Advisory Board
• Dr. Robert Friedlander M.D.,
  Consulting Chief Medical Officer
• Dr. Curt Bradshaw Ph.D.,
  Chief Scientific Officer
• Eric J Ende,
  Director
• Curt Bradshaw,
  Chief Scientific Officer
• Gerald J Mc Dougall,
  Director
• Kianoush Motesharei,
  See Remarks
• Todd P. Branning,
  Chief Financial Officer
• Corp Symetryx,
  10% owner
• Dietrich A Stephan,
  Founder and CEO